Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.22) by 13.64 percent. This is a 39.02 percent increase over losses of $(0.41) per share from the same period last year. The company reported quarterly sales of $7.670 million which missed the analyst consensus estimate of $11.947 million by 35.80 percent. This is a 60.10 percent decrease over sales of $19.223 million the same period last year.